Xiaodong Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaodong Huang has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Junlin Yi
Department of radiation oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
2 shared publications K. Wang
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 shared publications- Li Gao
Department of Obstetrics and Gynecology, The People’s Hospital of Yingshang, Anhui, China
2 shared publications - Yongguo Yu
Department of Pediatric Endocrinology and Genetics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications Yongnian Shen
Department of Endocrinology, Shanghai Children’s Medical Center , Shanghai Jiaotong University School of Medicine , Shanghai , P.R. China
2 shared publications- Yu Ding
Department of Endocrinology and Metabolism, Shanghai Children′s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, shsmu.edu.cn
2 shared publications
Latest Publications
- Open Access
- 2 April 2022
- Published by Springer Nature in Chinese Medicine
- Vol. 17 (1) , 1-8
Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial
Objective: To explore the effect of Ludangshen oral liquid for treatment of convalescent patients with coronavirus disease 2019 (COVID-19) with randomized, double-blind, placebo-controlled multicenter method. Methods: 200 convalescent COVID-19 patients who had symptoms related to decreased digestive and respiratory function were randomly divided to either receive Ludangshen oral liquid or placebo for 2 weeks. The severity of clinical symptoms including fatigue, anorexia, abdominal distension, loose stools, and shortness of breath were assessed by visual analogue scale and observed at before and after treatment. The improvement and resolution rates of clinical symptoms were evaluated. Full analysis set (FAS) and per-protocol set (PPS) were used for statistical analyses. Adverse events were recorded during the study. Results: 8 patients did not complete the study. After 2 weeks of treatment, both FAS and PPS results showed that patients in Ludangshen group had significantly lower score of fatigue, anorexia, loose stools, and shortness of breath than placebo group (P < 0.05), while there was no significant difference in distention (P > 0.05). The improvement rate of fatigue, anorexia, distension, loose stools and shortness of breath were significantly higher in Ludangshen group (P < 0.05), as well as the resolution rates (P < 0.05) except for shortness of breath (P > 0.05). There were two cases of adverse events, with one nose bleeding in Ludangshen group and one headache in placebo group. Conclusion: The study suggested that two weeks of Ludangshen oral liquid treatment may have certain effects for convalescent COVID-19 patients on improving digestive and respiratory symptoms including fatigue, anorexia, loose stools and shortness of breath, which may be one of the choices for management of convalescent COVID-19 patients with digestive and respiratory symptoms.
- 2 April 2022
- Published by Springer Nature in Chinese Medicine
- Vol. 17 (1) , 1-8
Open AccessLudangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial
Objective: To explore the effect of Ludangshen oral liquid for treatment of convalescent patients with coronavirus disease 2019 (COVID-19) with randomized, double-blind, placebo-controlled multicenter method. Methods: 200 convalescent COVID-19 patients who had symptoms related to decreased digestive and respiratory function were randomly divided to either receive Ludangshen oral liquid or placebo for 2 weeks. The severity of clinical symptoms including fatigue, anorexia, abdominal distension, loose stools, and shortness of breath were assessed by visual analogue scale and observed at before and after treatment. The improvement and resolution rates of clinical symptoms were evaluated. Full analysis set (FAS) and per-protocol set (PPS) were used for statistical analyses. Adverse events were recorded during the study. Results: 8 patients did not complete the study. After 2 weeks of treatment, both FAS and PPS results showed that patients in Ludangshen group had significantly lower score of fatigue, anorexia, loose stools, and shortness of breath than placebo group (P < 0.05), while there was no significant difference in distention (P > 0.05). The improvement rate of fatigue, anorexia, distension, loose stools and shortness of breath were significantly higher in Ludangshen group (P < 0.05), as well as the resolution rates (P < 0.05) except for shortness of breath (P > 0.05). There were two cases of adverse events, with one nose bleeding in Ludangshen group and one headache in placebo group. Conclusion: The study suggested that two weeks of Ludangshen oral liquid treatment may have certain effects for convalescent COVID-19 patients on improving digestive and respiratory symptoms including fatigue, anorexia, loose stools and shortness of breath, which may be one of the choices for management of convalescent COVID-19 patients with digestive and respiratory symptoms.
- Open Access
- 1 November 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 111 (3) , e482-e483
Stereotactic Body Radiation Therapy for the First-Line Comprehensive Treatment of Oligometastatic Nasopharyngeal Carcinoma: A Prospective, Single-Arm, Phase II Trial
- 1 November 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 111 (3) , e482-e483
Open AccessStereotactic Body Radiation Therapy for the First-Line Comprehensive Treatment of Oligometastatic Nasopharyngeal Carcinoma: A Prospective, Single-Arm, Phase II Trial
- 1 July 2021
- Published by Elsevier in Pathology - Research and Practice
- Vol. 223, 153460
Role and mechanism of action of circular RNA and laryngeal cancer
- 1 July 2021
- Published by Elsevier in Pathology - Research and Practice
- Vol. 223, 153460
Role and mechanism of action of circular RNA and laryngeal cancer
- Open Access
- 8 April 2021
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 17 (4) , 1512-1514
Correction to: Latent Membrane Protein 1 Promotes Tumorigenesis Through Upregulation of PGC1β Signaling Pathway
A Correction to this paper has been published: 10.1007/s12015-021-10160-8
- 8 April 2021
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 17 (4) , 1512-1514
Open AccessCorrection to: Latent Membrane Protein 1 Promotes Tumorigenesis Through Upregulation of PGC1β Signaling Pathway
A Correction to this paper has been published: 10.1007/s12015-021-10160-8
- Open Access
- 21 February 2018
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 31 (3) , 323-329
Evaluation of basal sex hormone levels for activation of the hypothalamic–pituitary–gonadal axis
Background: This study aimed to identify the predictive value of basal sex hormone levels for activation of the hypothalamic–pituitary–gonadal (HPG) axis in girls.Methods: Gonadotropin-releasing hormone (GnRH) stimulation tests were performed and evaluated in a total of 1750 girls with development of secondary sex characteristics. Correlation analyses were conducted between basal sex hormones and peak luteinizing hormone (LH) levels ≥5 IU/L during the GnRH stimulation test. Receiver operating characteristic (ROC) curves for basal levels of LH, follicle-stimulating hormone (FSH), LH/FSH, and estradiol (E2) before the GnRH stimulation test were plotted. The area under the curve (AUC) and 95% confidence intervals (CIs) were measured for each curve.Results: The maximum AUC value was observed for basal LH levels (0.77, 95% CI: 0.74–0.79), followed by basal FSH levels (0.73, 95% CI: 0.70–0.75), the basal LH/FSH ratio (0.68, 95% CI: 0.65–0.71), and basal E2 levels (0.61, 95% CI: 0.59–0.64). The appropriate cutoff value of basal LH levels associated with a positive response of the GnRH stimulation test was 0.35 IU/L, with a sensitivity of 63.96% and specificity of 76.3% from the ROC curves when Youden’s index showed the maximum value. When 100% of patients had peak LH levels ≥5 IU/L, basal LH values were >2.72 IU/L, but the specificity was only 5.45%.Conclusions: Increased basal LH levels are a significant predictor of a positive response during the GnRH stimulation test for assessing activation of the HPG axis in most girls with early pubertal signs.
- 21 February 2018
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 31 (3) , 323-329
Open AccessEvaluation of basal sex hormone levels for activation of the hypothalamic–pituitary–gonadal axis
Background: This study aimed to identify the predictive value of basal sex hormone levels for activation of the hypothalamic–pituitary–gonadal (HPG) axis in girls.Methods: Gonadotropin-releasing hormone (GnRH) stimulation tests were performed and evaluated in a total of 1750 girls with development of secondary sex characteristics. Correlation analyses were conducted between basal sex hormones and peak luteinizing hormone (LH) levels ≥5 IU/L during the GnRH stimulation test. Receiver operating characteristic (ROC) curves for basal levels of LH, follicle-stimulating hormone (FSH), LH/FSH, and estradiol (E2) before the GnRH stimulation test were plotted. The area under the curve (AUC) and 95% confidence intervals (CIs) were measured for each curve.Results: The maximum AUC value was observed for basal LH levels (0.77, 95% CI: 0.74–0.79), followed by basal FSH levels (0.73, 95% CI: 0.70–0.75), the basal LH/FSH ratio (0.68, 95% CI: 0.65–0.71), and basal E2 levels (0.61, 95% CI: 0.59–0.64). The appropriate cutoff value of basal LH levels associated with a positive response of the GnRH stimulation test was 0.35 IU/L, with a sensitivity of 63.96% and specificity of 76.3% from the ROC curves when Youden’s index showed the maximum value. When 100% of patients had peak LH levels ≥5 IU/L, basal LH values were >2.72 IU/L, but the specificity was only 5.45%.Conclusions: Increased basal LH levels are a significant predictor of a positive response during the GnRH stimulation test for assessing activation of the HPG axis in most girls with early pubertal signs.
- Open Access
- 15 March 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 44536
Diagnostic Application of Targeted Next-Generation Sequencing of 80 Genes Associated with Disorders of Sexual Development
Disorders of sexual development (DSD) are estimated to occur in 1 of 4500 births. Since the genetic etiology of DSD is highly heterogeneous, obtaining a definitive molecular diagnosis by single gene test is challenging. Utilizing a high-throughput sequencing upfront is proposed as an efficient approach to aid in the diagnosis. This study aimed to examine the diagnostic yield of next-generation sequencing in DSD. 32 DSD patients that previously received clinical examinations and single gene tests were selected, with or without a diagnosis. Prior single gene tests were masked, and then samples went through targeted next-generation sequencing of 80 genes from which the diagnostic yield was assessed. A likely diagnosis, with pathogenic or likely pathogenic variants identified, was obtained from nine of the 32 patients (i.e., 28.1%, versus 10% by single gene tests). In another five patients (15.6%), variants of uncertain significance were found. Among 18 variants identified (i.e., 17 single nucleotide variants and one small deletion), eight had not been previously reported. This study supports the notion that next-generation sequencing can be an efficient tool in the clinical diagnosis and variant discovery in DSD.
- 15 March 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 44536
Open AccessDiagnostic Application of Targeted Next-Generation Sequencing of 80 Genes Associated with Disorders of Sexual Development
Disorders of sexual development (DSD) are estimated to occur in 1 of 4500 births. Since the genetic etiology of DSD is highly heterogeneous, obtaining a definitive molecular diagnosis by single gene test is challenging. Utilizing a high-throughput sequencing upfront is proposed as an efficient approach to aid in the diagnosis. This study aimed to examine the diagnostic yield of next-generation sequencing in DSD. 32 DSD patients that previously received clinical examinations and single gene tests were selected, with or without a diagnosis. Prior single gene tests were masked, and then samples went through targeted next-generation sequencing of 80 genes from which the diagnostic yield was assessed. A likely diagnosis, with pathogenic or likely pathogenic variants identified, was obtained from nine of the 32 patients (i.e., 28.1%, versus 10% by single gene tests). In another five patients (15.6%), variants of uncertain significance were found. Among 18 variants identified (i.e., 17 single nucleotide variants and one small deletion), eight had not been previously reported. This study supports the notion that next-generation sequencing can be an efficient tool in the clinical diagnosis and variant discovery in DSD.
- Open Access
- 18 February 2016
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 13 (4) , 3127-3132
Novel mutations in the CYP11B2 gene causing aldosterone synthase deficiency
Aldosterone synthase deficiency (ASD) is a rare, autosomal recessive inherited disease. Mutations in the CYP11B2 gene are responsible for the occurrence of ASD, and the clinical manifestations of ASD vary with age. Affected infants may develop symptoms of mineralocorticoid deficiency, including clinical presentation with frequent vomiting, a variable degree of hyponatremia, hyperkalemia, and metabolic acidosis combined with poor growth, which are easily confused with several other endocrine genopathies, including pseudohypoaldosteronism type 1 and congenital adrenal hyperplasia. In the present study, whole exome sequencing (WES) was used to screen for causal variants in the genome of a Chinese pediatric patient with confusing endocrine disorder symptoms. Clinical symptoms of frequent vomiting, hyponatremia and hyperkalemia were selected as the filtering indices to analyze the WES data. Clinically relevant variants were subsequently verified using Sanger sequencing. Minigene construct analysis was used to assess the consequence of a splicing variant in the CYP11B2 gene. The compound heterozygous mutations, c.1009C>T and c.240‑1G>A, in the CYP11B2 gene were identified and confirmed, and represented novel variants. Sequence analysis results revealed that the c.1009C>T mutation at codon 337 of exon 6 was a nonsense mutation, which led to early termination of the protein translation process. In addition, further investigation of the splicing pattern in a minigene construct showed that the c.240‑1G>A mutation led to the preservation of intron 1, with the 3'‑splice site disappearing during transcriptional processing of the mRNA. Using molecular genetic assessments, the patient was finally diagnosed with ASD. Therefore, the present study identified two novel CYP11B2 gene mutations in a Chinese patient with ASD, indicating exome sequencing as an effective diagnostic tool for rare endocrine-metabolic diseases.
- 18 February 2016
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 13 (4) , 3127-3132
Open AccessNovel mutations in the CYP11B2 gene causing aldosterone synthase deficiency
Aldosterone synthase deficiency (ASD) is a rare, autosomal recessive inherited disease. Mutations in the CYP11B2 gene are responsible for the occurrence of ASD, and the clinical manifestations of ASD vary with age. Affected infants may develop symptoms of mineralocorticoid deficiency, including clinical presentation with frequent vomiting, a variable degree of hyponatremia, hyperkalemia, and metabolic acidosis combined with poor growth, which are easily confused with several other endocrine genopathies, including pseudohypoaldosteronism type 1 and congenital adrenal hyperplasia. In the present study, whole exome sequencing (WES) was used to screen for causal variants in the genome of a Chinese pediatric patient with confusing endocrine disorder symptoms. Clinical symptoms of frequent vomiting, hyponatremia and hyperkalemia were selected as the filtering indices to analyze the WES data. Clinically relevant variants were subsequently verified using Sanger sequencing. Minigene construct analysis was used to assess the consequence of a splicing variant in the CYP11B2 gene. The compound heterozygous mutations, c.1009C>T and c.240‑1G>A, in the CYP11B2 gene were identified and confirmed, and represented novel variants. Sequence analysis results revealed that the c.1009C>T mutation at codon 337 of exon 6 was a nonsense mutation, which led to early termination of the protein translation process. In addition, further investigation of the splicing pattern in a minigene construct showed that the c.240‑1G>A mutation led to the preservation of intron 1, with the 3'‑splice site disappearing during transcriptional processing of the mRNA. Using molecular genetic assessments, the patient was finally diagnosed with ASD. Therefore, the present study identified two novel CYP11B2 gene mutations in a Chinese patient with ASD, indicating exome sequencing as an effective diagnostic tool for rare endocrine-metabolic diseases.
- Open Access
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93 (3) , S128
The Value of Adding Chemotherapy to Intensity Modulated Radiation Therapy for Stage II Nasopharyngeal Carcinoma: A Multicenter Phase 2 Study
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93 (3) , S128
Open AccessThe Value of Adding Chemotherapy to Intensity Modulated Radiation Therapy for Stage II Nasopharyngeal Carcinoma: A Multicenter Phase 2 Study